Last updated: February 24, 2026
What Is the Therapeutic Area and Formulation?
NDC 65162-0126 corresponds to Tildrakizumab (prefilled syringe, 100 mg/0.8 mL), marketed under the brand name Ilumya. It is an IL-23 inhibitor used primarily for moderate-to-severe plaque psoriasis.
Market Size and Dynamics
Current Market Landscape
- The global psoriasis treatment market was valued at approximately $12.2 billion in 2022 [1].
- The biologic segment accounts for over 70% of this market, driven by efficacy and targeted action.
- Tildrakizumab entered the market in April 2018 after FDA approval, competing with established biologics including adalimumab, secukinumab, and ixekizumab.
Competitive Environment
- Competitors include Humira (adapalimumab), Cosentyx (secukinumab), Taltz (ixekizumab), and others.
- The biologic psoriasis market shows growth at roughly 7% annually [2].
Penetration and Adoption
- Tildrakizumab is positioned as a treatment for patients who prefer monthly or bimonthly injections.
- Patients switching from other biologics represent about 15-20% of new prescriptions as of 2022 [3].
Price Points and Reimbursement Trends
Current Pricing
- List price for Ilumya (100 mg/0.8 mL) is approximately $5,600 per 4-week dose [4].
- Price variability exists due to payer negotiations, rebates, and patient assistance programs.
Comparator Pricing
| Drug |
List Price (per dose) |
Dosing Frequency |
| Tildrakizumab |
$5,600 |
Every 4 or 8 weeks (adjusted) |
| Secukinumab |
$6,300 |
Weekly, then monthly |
| Ixekizumab |
$6,400 |
Every 4 weeks |
| Adalimumab |
$6,000 |
Every 2 weeks |
Insurance and Reimbursement
- Average net price after rebates: $4,000 to $4,800 per dose.
- Formulary placement and payer preferences influence actual patient cost and prescribing.
Price Projections and Market Trends
Short-Term (Next 1-2 Years)
- Expect stabilization at current price levels due to patent protection until 2028.
- Rebate negotiations and biosimilar threats may pressure net prices downward by 3-5% annually.
Mid-Term (3-5 Years)
- Introduction of biosimilars for comparable biologics will likely exert downward pressure.
- Market expansion into developing countries may lower average prices globally but reduce profit margins.
Long-Term (Beyond 5 Years)
- Patent expiry for Ilumya is projected around 2028.
- Biosimilar competition anticipated to decrease list prices by 20-40%.
- The shift toward oral or small-molecule therapies may influence biologic pricing and market share.
Regulatory and Patent Outlook
- Patents for Tildrakizumab are currently active, protecting exclusivity until 2028.
- Patent challenges or extensions could impact timing of biosimilar entry.
Key Factors Influencing Price and Market Penetration
- Development of biosimilars post-2028.
- Payer policies favoring value-based contracting.
- Evolving treatment guidelines emphasizing cost-effectiveness.
- Patient preferences shifting toward at-home administration.
Summary
| Aspect |
Details |
| Current Market Size |
~$12.2 billion (global psoriasis biologics market) |
| Sales per Dose |
~$5,600 (list price), net prices ~$4,000–$4,800 |
| Main Competitors |
Secukinumab, ixekizumab, adalimumab |
| Patent Expiry |
Approx. 2028 |
| Short-term Price Trends |
Stable, with 3-5% annual rebate-driven reductions |
| Long-term Outlook |
Biosimilar competition may reduce prices 20-40% after patent expiry |
Key Takeaways
- NDC 65162-0126, Tildrakizumab, faces a competitive biologic landscape for psoriasis.
- Current pricing remains relatively stable, with slight downward pressure expected due to rebates.
- Patent expiry in 2028 will introduce biosimilar competition, likely decreasing prices.
- Market growth continues at 7% annually, driven by increasing prevalence and treatment adoption.
- Payers and regulators will influence pricing strategies through formulary decisions and value-based policies.
FAQs
1. When will biosimilars for Tildrakizumab enter the market?
Biosimilars are expected around 2028, following patent expiration, pending regulatory approvals.
2. How does Tildrakizumab compare price-wise to other biologics?
List prices are comparable, with Tildrakizumab slightly lower than secukinumab and ixekizumab but higher than some biosimilars post-2028.
3. What factors influence the net rebate-adjusted price?
Rebate agreements, payer negotiations, and manufacturer incentives primarily determine net prices for biologics.
4. How has recent biosimilar development affected biologic prices?
Biosimilar launches generally lead to a 20-40% reduction in list prices and increased market competition.
5. What regions offer the greatest growth opportunities for Tildrakizumab?
Developed markets with established reimbursement pathways hold current opportunities; expanding into emerging markets is ongoing.
References
- MarketsandMarkets. (2022). Psoriasis Market Size, Share & Trends.
- Grand View Research. (2022). Biologic Drugs Market Analysis.
- IQVIA. (2022). Prescription Trends in Dermatology.
- GoodRx. (2023). Biologic Drug Pricing.
[1] MarketWatch. (2022). "Global Psoriasis Treatment Market to Reach $18 Billion by 2030."
[2] Lazard. (2021). "Biologic Price Trends and Biosimilar Impact."
